Evidence map›Paper›PMID 34495733›Full record

ArticleHealth affairs (Project Hope)2021

Myocardial Infarction Care Among The Elderly: Declining Treatment With Increasing Age In Two Countries.

John Hsu, Tor Iversen, Mary Price, Tron Anders Moger, Delaney Tevis, Terje P Hagen, William H Dow

Open access · greenAbstract read
In one paragraph

Article in Health affairs (Project Hope), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

John HsuJohn Hsu (john.hsu@mgh.harvard.edu) is director of the Clinical Economics and Policy Analysis Program at the Mongan Institute Health Policy Center, Massachusetts General Hospital, and an associate professor in the Department of Medicine and the Department of Health Care Policy, Harvard Medical School, both in Boston, Massachusetts.
Tor IversenTor Iversen is a professor in the Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo, in Oslo, Norway.
Mary PriceMary Price is a senior consulting data analyst at the Mongan Institute Health Policy Center, Massachusetts General Hospital.
Tron Anders MogerTron Anders Moger is a professor in the Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo.
Delaney TevisDelaney Tevis is a research assistant in the Mongan Institute Health Policy Research Center, Massachusetts General Hospital.
Terje P HagenTerje P. Hagen is professor and the head of the Institute of Health and Society, University of Oslo.
William H DowWilliam H. Dow is a professor in the Division of Health Policy and Management, School of Public Health, University of California Berkeley, in Berkeley, California.
University of Oslo · NOBerkeley Public Health Division · USInstitute of Health Economics · CAInstitute of Health Services and Policy Research · CAMGH Institute of Health Professions · USPolicy Analysis (United States) · US

Funding

Tradeoffs in the Design of Public Long-Term Care BenefitsP01AG032952 · NIA · HARVARD MEDICAL SCHOOL · PI John Michael McWilliams · 2009 to 2026
$39.0M
NIA NIH HHS P01 AG032952
6 · The paper itself

Abstract

The elderly account for the majority of medical spending in many countries, raising concerns about potentially unnecessary spending, especially during the final months of life. Using a well-defined starting point (hospitalization for an initial acute myocardial infarction) with evidence-based postevent treatments, we examined age trends in treatments in the US and Norway, two countries with high levels of per capita medical spending. After accounting for comorbidities, we found marked decreases within both countries in the use of invasive treatments with age (for example, less use of percutaneous coronary interventions and surgery) and the use of relatively inexpensive medications (for example, less use of anticholesterol [statin] drugs for which generic versions are widely available). The treatment decreases with age were larger in Norway compared with those in the US. The less frequent treatment of the oldest of the old, without even use of basic medications, suggests potential age-related bias and a disconnect with the evidence on treatment value. Hospital organization and payment in both countries should incentivize greater equity in treatment use across ages.

Indexed as

Hydroxymethylglutaryl-CoA Reductase InhibitorsMyocardial InfarctionAgedComorbidityHospitalizationHumansHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID34495733
PMCPMC10909380
OpenAlexW3196522926

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.